Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home | Companies

Nektar Therapeutics

Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco
United States of America
Phone: 1 415 4825300
Fax: 14-15-3395300
www.nektar.com

No. employees: 468
Turnover: 165.44 (US$m)
Financial year end: December

Company Overview

Top Competitors


Key Employees

Robert B. Chess

Chairman, Executive Board

Howard W. Robin

Director, Chief Executive Officer, President, Executive Board

Lutz Lingnau

Director, Non Executive Board

Roy A. Whitfield

Director, Non Executive Board

Dennis L. Winger

Director, Non Executive Board

Christopher A. Kuebler

Director, Non Executive Board

Joseph J. Krivulka

Director, Non Executive Board

R. Scott Greer

Director, Non Executive Board

Dorian Hirth

Senior Vice President - Human Resources and Facilities Operations, Senior Management

Stephen K. Doberstein, Ph.D.

Chief Scientific Officer, Senior Vice President, Senior Management

Maninder Hora, Ph.D.

Senior Vice President - Pharmaceutical Development and Manufacturing Operations, Senior Management

Gil M. Labrucherie

Senior Vice President, Chief Financial Officer, Senior Management

Jillian B. Thomsen

Senior Vice President - Finance, Chief Accounting Officer, Senior Management

John Nicholson

Senior Vice President, Chief Operating Officer, Senior Management

Ivan P. Gergel, M.D.

Senior Vice President - Drug Development, Chief Medical Officer, Senior Management

Deirdre BeVard

Vice President - Development Operations, Senior Management

Carlo J. Di Fonzo, Ph.D.

Vice President - Drug Development & Regulatory Affairs, Senior Management

Henk Kocken, Ph.D.

Vice President - Quality Assurance, Senior Management

Jennifer Ruddock

Senior Vice President - Investor Relations and Corporate Affairs , Senior Management

Mary Tagliaferri, M.D.

Vice President - Clinical Development, Senior Management

Mark A. Wilson

Vice President, General Counsel, Senior Management

Sunny Xie

Vice President - Biometrics and R&D systems, Senior Management

Jonathan Zalevsky, Ph.D.

Senior Vice President - Biology and Preclinical Development, Senior Management

Kevin Brodbeck, Ph.D.

Vice President - CMC Small Molecules, Senior Management

Michael A. Eldon, PhD.

Vice President - Clinical Pharmacology, Senior Management

Chulani Karunatilake, Ph.D.

Vice President - CMC Biologics, Senior Management

Locations/Subsidiaries


455 Mission Bay Boulevard South,
San Francisco,
California,
United States of America
Phone: 1 415 4825300
Fax: 1 415 3395300

1112 Church Street,
Huntsville,
Alabama,
United States of America
Phone: 1 256 5129200
Fax: 1 256 7047647

Nektar Therapeutics (India) Private Limited

Uptown Banjara, 3rd Floor,
Road No. 3, Banjara Hills,
Hyderabad,
Telangana,
India
Phone: 91 40 67204000
Fax: 91 40 67204099

Nektar Therapeutics UK, Ltd.

Unit 45/63,
Campus Road,
Bradford,
West Yorkshire,
United Kingdom
Phone: 44 1274 305540
Fax: 44 1274 305570

Products/Services


Products:

  • Movantik Tablets (naloxegol) - OIC in adult patients with chronic, non-cancer pain
  • Moventig (naloxegol) - OIC in adult patients who have had an inadequate response to laxatives
  • Pipeline:
  • NKTR-119 (naloxegol fixed-dose combination product) - Analgesic for pain
  • NKTR-171 - Neuropathic pain
  • NKTR-192 - Acute pain
  • NKTR-181 - Chronic pain
  • NKTR-196 - Acute pain
  • NKTR-195 - Visceral Pain
  • NKTR-174 - Neuropathic pain
  • Etirinotecan pegol (NKTR-102):
  • Metastatic Breast Cancer
  • Platinum-Resistant Ovarian Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • GI and solid tumors
  • Second-Line Colorectal Cancer
  • Bevacizumab (Avastin)-refractory high-grade glioma
  • Small Cell Lung Cancer (SCLC)
  • NKTR-214 - Immuno-oncology
  • Amikacin Inhale (NKTR-061) - Gram-negative pneumonia
  • Ciprofloxacin DPI - Non-cystic fibrosis bronchiectasis
  • NKTR-228 - Renal Disease
  • SEMPRANA (dihydroergotamine) - Migraine
  • Fovista - Neovascular Age-related Macular Degeneration
  • NKTR-223 - Gram-negative infections
  • BAX 855 (full-length longer-acting rFVIII molecule) - Hemophilia A
  • Longer-acting therapeutic clotting proteins - Hemophilia and bleeding disorders